Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

Part of paid clinical trials in Seattle, Washington.

Sponsor
Benaroya Research Institute
Study ID
NCT00349557
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the acute and late toxicities from radiation therapy in combination with bevacizumab (given every 2 weeks for 16 weeks then every 3 weeks for 12 weeks), bicalutamide (every day for 16 weeks) and goserelin (every 3 months for 2 years).

Key Dates

First listed
Jul 7, 2006
Start date
Apr 30, 2006
Status verified
Jul 2014

Study Design

Enrollment
18 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the acute (within 90 days from 1st day of radiation therapy) toxicities from intensity modulated radiation therapy (IMRT) in conjunction with bevacizumab, bicalutamide, and goserelin.

Locations (1)

FacilityCityStateZIPSite coordinators
Virginia Mason Medical CenterSeattleWashington98101-

Find similar trials in Seattle, WA

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Virginia Mason Medical Center· Seattle, WA

Related Studies